Online Program Home
My Program

CC = Vancouver Convention Centre   F = Fairmont Waterfront Vancouver
* = applied session       ! = JSM meeting theme

Activity Details

248 ! Mon, 7/30/2018, 2:00 PM - 3:50 PM CC-West 119
Statistical Issues Specific the Therapeutic Areas- 2 — Contributed Papers
Biopharmaceutical Section
Chair(s): Jie Li Jie Li
2:05 PM A Meta-Analysis to Indirectly Compare Experimental Drugs Across Multiple Indications Using a Bayesian Hierarchical Model

Ji Lin, Eli Lilly; Jingyi Liu, Eli Lilly; Zachary Thomas, Eli Lilly; Yumin Zhao, Eli Lilly & Co.; Mythili Koneru, Eli Lilly
2:20 PM Sample Size Determination Under Non-Proportional Hazards

Zhaowei Hua, Takeda Pharmaceuticals International Co.; Miao Yang, Oregon State University; Saran Vardhanabhuti, Takeda Pharmaceuticals
2:35 PM Are Tumor Size Changes Predictive of Survival for Immunotherapy Trials?
Meihua Wang, Merck & Co.; Thomas Jemielita, Merck & Co.; Cong Chen, Merck & Co.; Chen Hu, Johns Hopkins University
2:50 PM Does Phase 2 PFS or ORR Predict Phase 3 OS?
Russell Reeve, Quintiles
3:05 PM Innovative Approaches to Deal with Delayed Treatment Effect, Cure Fraction and Treatment Switching in Time-To-Event Data in Cancer Immuno-Therapies

Carl Di Casoli, Halozyme Therapeutics; Alessandro Previtali, Celgene; Jonathan Jaeger, Celgene; Marie-Laure Casaebaig, Celgene
3:20 PM A Simulation-Based Comparison Study About Different Methods Adjusting for the Bias of Treatment Non-Adherence

Jia Jia, AbbVie; Ying Zhang, Penn State College of Medicine; Jane Qian, Abbvie
3:35 PM Predictive Probability on Interim Analysis of Time-To-Event Endpoints with Delayed Treatment Effects

Matt Rosales, Astellas; Kentaro Takeda, Astellas Pharma Global Development, Inc.